Table 1.
Agonist | Chemical entity | Effects on drug taking and relapse | Dev. phase | Ref. |
---|---|---|---|---|
N/OFQ | peptidic | ↓ Alcohol intake | Preclinic | 36, 38 |
Ro 64-6198 | small molecule | ↓ ↑ Alcohol intake | Preclinic | 70, 82 |
Ro 64-6570 | small molecule | Not tested | Preclinic | 71 |
W212393 | small molecule | Not tested | Preclinic | 72 |
GRT6005 | small molecule | Not tested | Clinic | NCT01725087 |
SCH 655842 | small molecule | Not tested | Preclinic | 74 |
SCH 221510 | small molecule | Not tested | Preclinic | 75 |
UFP-112 | peptidic | ↓ Alcohol intake | Preclinic | 70 |
UFP-102 | peptidic | ↓ Alcohol intake | Preclinic | 70 |
OS-462 | peptidic | ↓ Alcohol intake | Preclinic | 70 |
Buprenorphine * | small molecule | ↓ Alcohol intake | Clinic | 46 |
SCH 486757 | small molecule | Not tested | Clinic | 73 |
NCT00230230 | ||||
Antagonist | ||||
UFP-101 | peptidic | — Alcohol intake | Preclinic | 46 |
J113397 | small molecule | Not tested | Preclinic | 76 |
NiK-21273 | small molecule | Not tested | Preclinic | 77 |
Compound 24 | small molecule | Not tested | Preclinic | 78 |
SB-612111 | small molecule | Not tested | Preclinic | 79 |
Nphe | peptidic | — Alcohol intake | Preclinic | 80 |
GF-4 | peptidic | Not tested | Preclinic | 81 |
Buprenorphine-induced alcohol drinking reduction is mediated by NOP.